Ludwig scientists around the world are continually making discoveries that alter our understanding of cancer. Our science is featured in the most prestigious journals and in general media. Explore some of our most recent findings, news and reports.
For media inquiries, contact
Vice President for Communications
Ludwig Institute for Cancer Research to present seven abstracts on advancements in cancer research at the AACR annual meeting
March 31, 2012, New York, NY,—The Ludwig Institute for Cancer Research announced today that scientists from its Institute will present seven abstracts at the America Association of Cancer Research (AACR) Annual Meeting 2012 taking place Saturday, March 31 to Wednesday, April 4, 2012, at McCormick Place in Chicago, Ill.
“Science presented at this year’s meeting advances cancer research in important ways. The more approaches we have, the better our chances are of preventing cancers from developing in the first place and of improving patient outcomes for those who do develop the disease,” said Andrew Simpson, Ph.D., Scientific Director for the Ludwig Institute for Cancer Research.
Institute abstracts to be presented at the AACR annual meeting include:
Evaluation of HPV infection in penile cancer and its association with p16 and MGMT protein expression levels and pathologic variables.
Kagohara L, et al.
Poster Session: April 2, 2012, Time: 8:00 am to 12:00 pm, McCormick Place West (Hall F), Poster section 5, Board: 26.
Luisa Villa, LICR São Paulo
Lara Termini, LICR São Paulo
Maria A. Andreoli, LICR São Paulo
Villin expression is frequently lost in colon cancers with microsatellite instability.
Arango D, et al.
Poster Session: April 3, Time: 1:00 – 5:00 pm, McCormick Place West (Hall F), Poster Section 15, Board: 17.
Sheren Al-Obaidi, LICR Melbourne
David S. Williams, LICR Melbourne
Georgia A. Corner, LICR Melbourne
Carmel Murone, LICR Melbourne
Lars Togel, LICR Melbourne
John Martin Mariadason, LICR Melbourne
miRNA-362-3p is associated with recurrence of colorectal cancer and targets E2F1, USF2 and PTPN1.
Tobiasen H, et al.
Poster Session: Tuesday, April 3, Time: 1:00 to 5:00 pm, McCormick Place West (Hall F), Poster Section 8, Board: 12.
Oliver M. Sieber, LICR Melbourne
Peter Gibbs, LICR Melbourne
Serum regulates reovirus-mediated cytopathy in K-Ras activated colorectal cancer and intestinal epithelial cell lines.
Maitra R, et al.
Poster Session: April 3, Time: 1:00 to 5:00 pm, McCormick Place West (Hall F), Poster Section 20, Board: 7.
John Martin Mariadason, LICR Melbourne
The gp130/Stat3 pathway enables Wnt induced regeneration and tumorigenesis in the mouse intestine.
Poster Session: April 3, Time: 1:00 to 5:00 pm, McCormick Place West (Hall F), Poster Section 3, Board: 29.
Toby Phesse, LICR, Melbourne
The upregulation of BTLA and PD-1 defines a novel subset of dysfunctional tumor antigen-specific CD8+ T cells.
Fourcade J, et al.
Poster Session: Wednesday, April 4, Time: 8:00 am to 12:00 pm, McCormick Place West (Hall F), Poster Section 20, Board: 15.
Philippe Guillaume, LICR Lausanne
Immanuel Luescher, LICR Lausanne
Genomic profiling of primary mucinous adenocarcinomas of the ovary.
Ryland G, et al.
Poster Session: Wednesday, April 4, Time: 8:00 am to 12:00 pm, McCormick Place West (Hall F), Poster Section 9, Board: 18.
Michael Christie, LICR Melbourne
About the Ludwig Institute for Cancer Research
LICR is an international non-profit organization committed to improving the understanding and control of cancer through integrated laboratory and clinical discovery. Leveraging its worldwide network of investigators and the ability to sponsor and conduct its own clinical trials, the Institute is actively engaged in translating its discoveries into applications for patient benefit. Since its establishment in 1971, the Institute has expended more than $1.5 billion on cancer research.